Peptides: GHK-Cu — Copper Tripeptide Science
GHK-Cu plasma levels decline from ~200ng/mL at age 20 to ~80ng/mL at age 60. Topical GHK-Cu showed significant fine line reduction vs placebo in human trials (Pickart 2012, PMID 23194977).
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | B (topical) / C (injectable) | grade | Topical GHK-Cu has Grade B human trial data for skin aging; injectable form has Grade C (insufficient human trials) |
| Age-Related Decline | ~60 | % | GHK-Cu plasma levels decline from ~200ng/mL at age 20 to ~80ng/mL at age 60 |
| Plasma Level at Age 20 | ~200 | ng/mL | Peak endogenous GHK-Cu concentration in young adults |
| Plasma Level at Age 60 | ~80 | ng/mL | GHK-Cu concentration in 60-year-olds — 60% below peak |
| Structure | Glycine-Histidine-Lysine + Cu²⁺ | composition | Naturally occurring tripeptide; copper(II) ion binding dramatically amplifies biological activity |
| Collagen Types Upregulated | Type I and III | collagen types | GHK-Cu increases synthesis of collagen type I (structural) and type III (wound repair) in fibroblast studies |
| INCI Name (Cosmetic) | Copper tripeptide-1 | regulatory name | Legally used cosmetic ingredient in EU and USA under this INCI designation |
GHK-Cu is one of the few peptides covered on this site with meaningful human evidence — specifically for topical skin applications. Understanding what it is, what it does, and where the evidence actually holds up is the goal of this page.
What GHK-Cu Is
GHK-Cu is the copper(II) chelate of the tripeptide glycine-histidine-lysine (GHK). It is a naturally occurring compound found in human plasma, urine, and saliva. The peptide itself is a matrikine — a bioactive fragment derived from the extracellular matrix (specifically the α2(I) chain of collagen type I). For more on the matrikine class, see the matrikines overview.
The copper ion is not incidental. GHK alone has modest biological activity. GHK-Cu — with the copper(II) ion chelated to the histidine residue — has substantially amplified wound-healing, collagen-stimulating, and antioxidant properties. This is why copper content matters in formulations, and why chelated forms are more relevant than GHK peptide alone.
Age-Related Decline
GHK-Cu concentration in human plasma declines approximately 60% between ages 20 and 60. At age 20, plasma concentrations run approximately 200ng/mL; by age 60, concentrations average approximately 80ng/mL. This decline correlates temporally with the reduction in skin regenerative capacity, wound healing speed, and collagen density that characterizes aging skin — though correlation does not establish causation.
Mechanisms of Action
Four distinct mechanisms have been characterized in human cell culture and animal studies:
- Wound healing: GHK-Cu upregulates TGF-β, VEGF, and various growth factors that accelerate wound closure and tissue repair
- Collagen synthesis: Increases production of collagen types I and III, elastin, and fibronectin in dermal fibroblasts
- Antioxidant protection: Binds free copper ions in tissue, reducing copper-catalyzed oxidative damage (the Fenton reaction)
- Anti-inflammatory: Downregulates pro-inflammatory cytokines including IL-1β and TNF-α
Evidence by Application
| Application | Mechanism | Evidence Grade | Practical Form | Notes |
|---|---|---|---|---|
| Wound healing (topical) | TGF-β, VEGF upregulation | B — human pilot trials | Topical cream/gel | Finkley 1997 demonstrated improved healing vs control |
| Skin aging (topical) | Collagen I/III synthesis; antioxidant | B — human RCTs and comparative trials | Topical cosmetic (Copper tripeptide-1) | Significant fine line reduction in multiple trials |
| Collagen synthesis stimulation | Fibroblast receptor activation | B (in vitro/human cell) | Topical; possibly injectable | Well-characterized in human fibroblast culture |
| Angiogenesis | VEGF upregulation | C — primarily animal | Injectable (experimental) | Rat wound models; mechanism conserved in humans likely |
| Anti-inflammatory | Cytokine modulation | C — in vitro/animal | Various | No large human trials for anti-inflammatory endpoint |
| Injectable systemic use | Multiple pathways | C — animal studies | Injectable research chemical | No human RCTs; insufficient safety data |
Legal Status by Jurisdiction
| Jurisdiction | Status | Schedule | Notes |
|---|---|---|---|
| USA | OTC cosmetic ingredient (topical); research chemical (injectable) | None (DEA unscheduled) | INCI name Copper tripeptide-1 is legal OTC cosmetic; injectable is unscheduled research chemical |
| UK | Legal cosmetic ingredient (topical); not scheduled (injectable) | Not scheduled | Copper tripeptide-1 widely used in UK cosmetic products |
| Australia | Legal cosmetic ingredient (topical); Schedule 4 (injectable) | Schedule 4 for injectable | TGA Schedule 4 applies to injectable peptides; topical cosmetic use legal |
| Canada | Legal cosmetic ingredient; not a controlled substance | No schedule | Health Canada allows cosmetic use; injectable is gray market |
| EU | Legal cosmetic ingredient (INCI: Copper tripeptide-1); injectable unscheduled | No harmonized schedule | Used widely in EU skincare; injectable generally unscheduled |
Topical vs. Injectable: The Evidence Asymmetry
This is worth stating plainly: the human evidence for GHK-Cu exists almost entirely for topical application. Multiple human trials using topical GHK-Cu formulations have shown measurable improvements in fine lines, skin elasticity, and wound healing. These trials range from small pilot studies to larger comparative trials.
Injectable GHK-Cu is a different matter. Animal studies show systemic effects from injected GHK-Cu, but there are no completed human RCTs for injectable use, no established safe dosing range in humans, and no characterized human pharmacokinetics for the injectable route. Users who pursue injectable GHK-Cu should understand they are extrapolating from animal data, not following evidence-based human trial protocols.
For skin-focused goals, topical application via products containing Copper tripeptide-1 (INCI name) is both the evidence-supported and legally straightforward route.
Related Pages
Sources
- Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Rejuvenation Res. 2012;15(6):604-12. PMID 23194977
- Finkley MB et al. Pilot comparative study on the topical treatment of photoaged facial skin. Am J Cosmetic Surg. 1997;14(2):153-159.
- Lunde NN et al. Copper peptide GHK-Cu and skin aging. PMID 26380991
Frequently Asked Questions
What does GHK-Cu actually do to skin?
GHK-Cu upregulates TGF-β and VEGF, stimulating fibroblast production of collagen types I and III and fibronectin. It also has antioxidant effects by binding free copper ions, reducing oxidative damage to collagen fibers. Human trials have demonstrated measurable reduction in fine lines and improvement in skin elasticity with topical application over 8–12 weeks.
Is injectable GHK-Cu better than topical?
Not necessarily, and the evidence base for injectable GHK-Cu is much weaker. Topical GHK-Cu has Grade B human trial data. Injectable forms have been studied primarily in animal models (Grade C). For skin-related applications, topical delivery is the evidence-supported route. Injectable use is experimental with an insufficient human safety and efficacy profile.
What is the INCI name for GHK-Cu in cosmetics?
The INCI (International Nomenclature of Cosmetic Ingredients) name is Copper tripeptide-1. This designation allows GHK-Cu to be used legally as a cosmetic ingredient in the EU, USA, and most other markets. Products sold containing this ingredient as a topical cosmetic are legal and do not require a prescription.